Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemox + Anlotinib + Sintilimab in Advanced cHCC-CCA
NCT06033118Phase 2Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Oct 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and sintilimab in Combined hepatocellular-cholangiocarcinoma (cHCC-CC), sponsored by Sichuan University. Primary endpoint: Objective Response Rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
anlotinibsintilimab
03
Conditions
Combined hepatocellular-cholangiocarcinoma (cHCC-CC)
Beyond the preview
Go deeper on NCT06033118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033118.